Zeitschrift für Schmerz und Linderung

Abstrakt

Spinal Analgesic Drug Delivery for Ehlers-Danlos Hypermobility Type Chronic Pain Treatment: A Case Report

Van Tilburg CWJ

Study background: Chronic pain in patients with Ehlers-Danlos hypermobility type can be a severe, debilitating disorder. Scientific literature on pain treatment in these patients is scarce. We present a case report on spinal analgesic drug delivery for diminishing pain. Methods: Multidisciplinary consultation in adult female patient with Ehlers-Danlos, hypermobility type. Implanting Synchromed® II pump (Medtronic, Minneapolis, MN, United States of America) after successful trial period. One year follow-up. Results: During the trial period, verbal Numerical Rating Scale decreased from 8 to 3 with 0.72 mg of spinal morphine (2 mg/mL, 0.36 mL/day) and no oral or transdermal opioids. The spinal morphine/hydromorphone infusion schemes and verbal NRS for pain after implantation are presented. Baseline and follow-up results at one year from the other questionnaires are presented. Wound healing was successful. Conclusion: Spinal analgesic drug delivery can be an option to treat chronic, widespread pain in patients with Ehlers-Danlos syndrome, hypermobility type. Multidisciplinary consultation is necessary to deal with the wide variety of problems in these patients